Maravai LifeSciences Holdings Inc
MRVI2.870USD
-0.020-0.69%
收盘 11/07, 16:00（美东）报价延迟15分钟
415.05M总市值
亏损市盈率 TTM
关于 Maravai LifeSciences Holdings Inc 公司
Maravai LifeSciences Holdings, Inc. 是一家生命科学公司，提供关键产品以促进药物疗法、诊断和新型疫苗的开发并支持人类疾病的研究。其部门包括核酸生产部门和生物制剂安全测试部门。核酸生产部门专注于制造和销售高度改良的核酸产品，以满足客户的研究、治疗和疫苗计划的需求。该部门的业务部门包括 TriLink Discovery、TriLink GMP、Glen Research 和 Alphazyme。生物制剂安全测试部门专注于制造和销售生物制剂安全和杂质测试以及检测开发服务，客户可在生物药物制造活动中使用这些服务。该部门的业务由 Cygnus Technologies 组成。它为各种公司提供服务，包括生物制药、疫苗、诊断以及细胞和基因治疗。
Maravai LifeSciences Holdings Inc简介
公司代码MRVI
公司名称Maravai LifeSciences Holdings Inc
上市日期Nov 20, 2020
CEOMr. Bernd Brust
员工数量570
证券类型Ordinary Share
年结日Nov 20
公司地址10770 Wateridge Circle Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18585460004
网址https://www.maravai.com/
公司代码MRVI
上市日期Nov 20, 2020
CEOMr. Bernd Brust
Maravai LifeSciences Holdings Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
75.77K
-54.05%
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
North America
30.64M
64.64%
Europe, the Middle East and Africa
8.39M
17.71%
Asia Pacific
8.16M
17.21%
Latin and Central America
327.00K
0.69%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
GTCR Golder Rauner, LLC
13.93%
12 West Capital Management, L.P.
8.65%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.77%
The Vanguard Group, Inc.
4.93%
其他
60.91%
持股股东
持股股东
占比
GTCR Golder Rauner, LLC
13.93%
12 West Capital Management, L.P.
8.65%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.77%
The Vanguard Group, Inc.
4.93%
其他
60.91%
股东类型
持股股东
占比
Investment Advisor
27.99%
Hedge Fund
26.51%
Investment Advisor/Hedge Fund
16.20%
Private Equity
13.93%
Individual Investor
6.19%
Corporation
4.75%
Research Firm
3.82%
Pension Fund
0.20%
Bank and Trust
0.16%
其他
0.26%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GTCR Golder Rauner, LLC
20.15M
13.93%
--
--
Jun 30, 2025
12 West Capital Management, L.P.
12.52M
8.65%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
5.81%
+52.73K
+0.63%
Jun 30, 2025
Braidwell LP
8.35M
5.77%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
9.38M
6.48%
-2.26M
-19.38%
Jun 30, 2025
Hudson View Capital LLC
6.87M
4.75%
+6.87M
--
May 21, 2025
Mackenzie Investments
6.07M
4.2%
-44.32K
-0.72%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
2.89%
+75.50K
+1.84%
Jun 30, 2025
Mirabella Financial Services LLP
3.75M
2.59%
+10.05K
+0.27%
Jun 30, 2025
Point72 (DIFC) Ltd
3.72M
2.57%
+2.16M
+138.99%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Global X Genomics & Biotechnology ETF
0.39%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Global X Genomics & Biotechnology ETF
占比0.39%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
iShares Biotechnology ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
